Kringle Pharma,Inc. (4884) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-09-24 | — | Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury | |
| 2026-08-10 | Earnings Release | Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated) | |
| 2026-07-24 | — | Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.